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Despite a declining incidence during the past 60 years, gastric
cancer is still among the most common cancers in Europe (World
Health Organization, 1998). Metastatic gastric cancer remains an
incurable disease with a median survival time of only 4–8 months.
Randomized studies have demonstrated a survival benefit and
impact on quality of life for patients with irresectable or metastatic
gastric cancer treated with chemotherapy plus supportive care as
compared to best supportive care alone (Pyrhönen et al, 1995;
Glimelius et al, 1997). Thus, chemotherapy for advanced gastric
cancer is now widely accepted in Europe and the US. A number of
drugs have demonstrated activity such as 5-fluorouracil (5-FU),
etoposide, doxorubicin, methotrexate and cisplatin. Combination
regimens, usually based on 5-FU, have achieved response rates
between 20 and 40% (Schipper and Wagener, 1996; Wils, 1996).
Several studies have shown that the combination of 5-FU and
cisplatin is active and well tolerated in patients with gastric cancer
(Okada et al, 1991; Kim et al, 1993; Rougier et al, 1994; Wilke et
al, 1996a).
Paclitaxel is an antimitotic agent with the unique cytotoxic
mechanism of tubulin stabilization and polymerization, resulting
in nonfunctional microtubules (Rowinsky et al, 1990). Paclitaxel
exhibits an antitumour activity against various tumours including
gastric cancer cell lines (Vanhoefer et al, 1995; Chang et al, 1996).
Ajani et al obtained a 17% response rate using paclitaxel as a
single agent in gastric cancer, with a tendency towards a higher
response rate in patients receiving paclitaxel as continuous infu-
sion over 24 hours. A 22% response rate was observed in
pretreated patients with gastric cancer by Cascinu et al, with pacli-
taxel as single agent administered over 3 hours (Ajani et al, 1998;
Cascinu et al, 1998). Studies investigating the combination of
paclitaxel with 5-FU revealed response rates between 15 and 50%,
associated with a rather low toxicity profile (Cascinu et al, 1997;
Murad, 1999). We have reported the results for the combination of
5-FU given as a weekly 24-hour continuous infusion plus folinic
acid for 6 consecutive weeks in combination with paclitaxel at 3
weekly intervals (Bokemeyer et al, 1997a). A response rate of
32% was observed in 22 chemonaive gastric cancer patients
resulting in a progression-free and overall survival of 8 and 11
months, respectively. Toxicity was mild with neutropenia (14%),
alopecia (45%) and nausea and vomiting (5%) being the most
frequent WHO grade III/IV toxicities (Bokemeyer et al, 1997a).
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Summary To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-
FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts
(28 male and 17 female) with a median age of 60 years (range 35–74) were enrolled. 5-FU 2 g/m2 was given weekly over 24 h i.v. preceded by
folinic acid 500 mg/m2 as a 2 h infusion. Paclitaxel 175 mg/m2 was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m2 as
1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median
of 3 cycles (range 1–4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11%) obtained a CR and 18 pts
(40%) a PR (ORR 51%; 95% Cl: 35.8–66.3%). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour.
Nine pts (20%) had stable disease. Thirteen pts (29%) were considered to have failed treatment, 8 pts (18%) due to progressive disease and
5 pts (11%) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall
survival times were 9 months (range 1–36+) and 14 months (range 2–36+), respectively. Neutropenia WHO III°/IV° occurred in 7 pts (15%) with
only 1 pt having grade IV. Additional non-haematologic WHO III°/IV° toxicities included nausea/vomiting in 5 (11%), alopecia in 22 (49%), and
diarrhoea in 1 patient each (2%). Dose reductions or treatment delays were necessary in 8 pts (17%), mainly due to neutropenia. All pts were
treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active
regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may
also be an attractive option to be tested for neoadjuvant or adjuvant treatment. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1295, available online at http://www.idealibrary.com on Two recent studies examined the combination of paclitaxel,
cisplatin and 5-FU in patients with locally advanced adenocarci-
noma of the oesophagus in the neoadjuvant setting, as well as in
patients with metastatic disease. A high response rate combined
with an acceptable toxicity was reported (Belani et al, 1997; Ilson
et al, 1998).
Based on the activity of 5-FU and cisplatin in gastric cancer and
on the favourable results of the combination of 5-FU/folinic acid
and paclitaxel, we here present a phase II study combining weekly
24 h continuous infusion 5-FU/folinic acid with cisplatin and
paclitaxel in an alternating schedule in patients with gastric cancer.
PATIENTS AND METHODS
Patients
Patients with histologically proven advanced or metastatic gastric
cancer were included in this study. Inclusion criteria were as
follows: unresectable, locally-advanced or metastatic disease;
ECOG performance status 0–2; presence of measurable disease;
age between 18 and 75 years; life expectancy > 3 months; no prior
chemotherapy; adequate haematological, renal and hepatic func-
tion as defined by a granulocyte count ³ 1.5 ´ 109/l, thrombocytes
³ 100 ´ 109/1, serum creatinine ≤ 1.5 mg/dl, creatinine clearance 
³ 60 ml/min, bilirubin level < 2-fold and liver enzymes < 3-fold
the upper normal limits and written informed consent. All patients
had to be available for follow-up.
Patients were excluded from the study in case of one of the
following: active bleeding, diffuse, non-measurable liver metas-
tases; history of a secondary malignancy except for non-
melanomatous skin cancer or carcinoma in situ of the cervix;
concurrent insufficiently treated disease such as heart, renal or
hepatic failure or uncontrolled infection; prior chemotherapy;
presence of a concurrent psychiatric disorder; pregnancy.
Prior to therapy, a clinical history and physical examination, a
complete blood count and serum chemistry including liver and
kidney function tests, a creatinine clearance as well as an electro-
cardiogram and an audiogram were obtained. All measurable
tumour lesions were radiologically assessed either by CT-scan,
chest-X-ray or abdominal ultrasound.
The study was approved by the Ethics Committee of the
University of Tuebingen.
Treatment plan
Treatment was given once weekly for a total of 6 weeks followed
by 2 weeks rest. This period was defined as one treatment cycle
(Figure 1). 5-Fluorouracil was administered weekly at a dose of
2000 mg/m2 as 24 h-continuous infusion preceded by 500 mg/m2
folic acid as a 2 h infusion. Paclitaxel was administered at a dose
of 175 mg/m2 on days 1 and 22 as a 3 h infusion. All patients
received dexamethasone 20 mg, ranitidine 300 mg as well as
diphenhydramine 50 mg 30 minutes prior to paclitaxel in order to
avoid hypersensitivity reactions. Cisplatin 50 mg/m2 was added on
days 8 and 29 to the 24 h-infusion 5-FU backbone of the regimen.
All patients received adequate antiemetic pre-medication prior to
chemotherapy. A permanent venous access (PORT-A-Cath, Baxter
Inc Germany) was implanted in all patients in order to facilitate the
continuous 5-FU application. Portable single use 24 h infusion
pumps (Infusor LV 5®, Baxter Inc, Germany) were used for the
ambulatory application of 5-FU. All patients were treated on an
outpatient basis.
Response and toxicity evaluation
Complete blood count, history and physical examination were
recorded weekly. Renal and liver function tests were assessed bi-
weekly in order to evaluate toxicity. Prior to each cycle, creatinine
clearance, audiogram and electrocardiogram were rechecked.
Toxicity was recorded every week based on WHO Toxicity Criteria.
Dose modifications and treatment delays were performed as neces-
sary according to the extent of the haematological and clinical toxi-
city. Planned dose modifications included the following: 25% dose
reduction of paclitaxel and cisplatin in case of WHO grade 2 periph-
eral neurotoxicity; stop of paclitaxel and cisplatin in case of WHO
grade 3/4 peripheral neurotoxicity; a 25% dose reduction of pacli-
taxel and/or 5-FU in case of WHO grade 3/4 granulocytopenia; 25%
dose reduction of all 3 drugs in case of mucositis WHO grade ³ 2. A
1-week treatment delay was planned in case of a WHO grade 3–4
toxicity, that had not resolved by the next week of treatment. Growth
factors were not routinely used in the present study.
Baseline assessment of subjective symptoms (abdominal pain,
vomiting, pain, loss of appetite, loss of weight) was performed
with a modified EORTC-questionnaire by the patients themselves
and their changes in intensity were recorded at the beginning, in
the middle and at the end of each cycle. Patients were asked to
grade their symptoms (absent, low, moderate, or severe) as well as
their overall health status and quality of life on a scale reaching
from 0 (very bad) to 100 (excellent). Questionaires were delivered
by the treating physician and were to be completed prior to
chemotherapy application.
Assessment of measurable disease was performed after each
cycle according to WHO criteria (Miller et al, 1981). Complete
remission (CR) was defined as the complete disappearance of all
clinical, radiological and biochemical evidence of the disease and
partial response as a greater than 50% reduction of all measurable
tumour lesions lasting for at least 4 weeks. Stable disease was
considered for all patients who achieved less than a partial
response but no evidence of progressive disease (new lesions or
increase in any area of measurable disease >25%). Treatment was
continued if the patient showed a remission or stable disease. A
maximum of 3 treatment cycles were planned per patient.
Study endpoints
Objectives of the present study were the determination of the
overall (complete and partial) response rate, the median progres-
sion-free survival (PFS), the overall survival (OS) and the toxicity
of the treatment. PFS, follow-up duration and OS were calculated
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Figure 1 Treatment planfrom the start of treatment to the date of disease progression or the
date of the last evaluation or death, respectively. Survival curves
were estimated by the method of Kaplan-Meier (Kaplan and
Meier, 1958). All statistics was performed using SAS software
(SAS Institute, Cary, NC, version 6.11). Quality of life question-
aires were descriptively analysed.
RESULTS
Forty-five patients with a median age of 60 years [35–75 years]
were enrolled in the study. Patient characteristics are given in
Table 1. Tumour at the primary site, lymph nodes and liver metas-
tases as well as peritoneal metastases were the most common
tumour sites and all patients had bidimensionally measurable
tumour lesions. Fourteen patients had undergone gastrectomy
prior to chemotherapy and 2 patients had received a gastroenteros-
tomy.
Response and survival
All patients were assessable for response and survival. Overall, 96
complete treatment cycles were administered to the 45 patients
(median 3 cycles per patient; range 0–3 cycles). Five patients
(11%) did not receive one complete treatment cycle for the
following reasons: one patient refused further therapy due to
WHO grade III° nausea and vomiting; one patient died of tumour
bleeding following the second week of therapy; 3 patients were
removed from therapy due to 5-FU related central neurotoxicity (1
patient), 5-FU-related cardiotoxicity with angina pectoris (1
patient) and a severe anaphylactic reaction to paclitaxel (1 patient).
These patients were considered as treatment failures.
Twenty-three patients [51%; 95% CI: 35.8–66.3.0%] achieved
an objective response including 5 complete remissions (11%).
Nine patients (20%) had stable disease as the best response to
therapy and the remaining 8 patients (18%) developed progressive
disease during treatment. Taking only the 40 patients into account,
who received at least one complete cycle of therapy, the overall
response rate was 58% [95% CI: 40.9–73.0%]. Responses
occurred mainly at the primary tumour site and at liver, lymph
node and lung metastases. The first patient with a complete remis-
sion presented with tumour at the primary site, liver metastases, an
adrenal metastasis as well as a soft tissue metastasis. Following
palliative gastrectomy and 3 cycles of chemotherapy complete
remission was proven by CT scan. In two patients a complete
remission, as confirmed by CT scan, was obtained after 3 cycles of
chemotherapy for tumour at the primary site and liver metastases.
One of these patients had had a palliative partial gastrectomy prior
to chemotherapy. Two further patients with metastatic disease to
the liver and to the lymph nodes and peritoneum had undergone a
gastrectomy prior to chemotherapy. Both subsequently received 3
cycles of chemotherapy and a complete remission was confirmed
by CT-scan. Two of these 5 patients relapsed, both at their initial
disease sites. The durations of complete responses are currently
8+, 13, 18+, 36 and 36+ months.
Interestingly, 7 of 15 assessable patients with, among others,
peritoneal metastases achieved a remission in the peritoneum, two
patients a complete and five patients a partial remission. All remis-
sion evaluations were based on CT scan (not confirmed by
laparoscopy). After a median follow-up of 14 months [1–36+], 17
patients have died of their disease and twenty-three patients are
alive with 6 of them having progressive disease. Seven patients
received a second-line chemotherapy, 4 of them mitomycin C
(Hartmann et al, 1999). The median progression-free and overall
survival are 9 (range 1–36+ months; 95% CI: 7–11) and 14 months
(range 2–36+; 95% CI: 7–21), respectively.
Quality of life questionnaires were obtained from 32 patients
and revealed an improvement in symptoms and overall well being
in 14 patients (44%) and a subjectively stable condition in 12
patients (38%). Only 6 patients (19%) complained about a
worsening of symptoms and physical well-being during therapy.
Improvement of symptoms and overall well-being was clearly
associated with tumour response. Twenty patients with an objec-
tive response and 6 patients with stable disease reported an
improvement or stable status following therapy. Progressive
disease was accompanied by a deterioration of symptoms in 4
patients. Only 1 patient who had obtained a complete remission
complained about a worsening of symptoms and 1 patient with
progressive disease reported an improvement of symptoms.
Toxicity
Toxicity according to WHO criteria was assessable in all 45
patients and is listed in Table 3 as the worst toxicity per patient
during the total study period. Seven patients (15%) developed a
WHO grade III/IV neutropenia. Based on the total number of
cycles completed, neutropenia occurred in 17 of 96 cycles (18%).
The duration of neutropenia was generally short and resolved
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Table 1 Patient characteristics (n = 45)
Characteristic No. of patients (%)
Median age 60 [35–74]
Male/female 28 (62)/17 (38)
ECOG performance status (median) 1 [0–2]
Gastric adenocarcinoma 45 (100)
Prior surgery
Gastrectomy 14 (31)
Other 2 (4)
Metastatic sites
Tumour at the primary sitea 26 (58)
Lymph nodes 31 (68)
Liver 17 (38)
Peritoneuma 15 (33)
Lungs 5 (11)
Bone 3 (7)
Other 8 (18)
Median follow up 14 months (1–36 months)
aAll patients with tumour at the primary site or peritoneal metastases had
additional measurable lesions
Table 2 Response and survival in 45 patients
Response No. of patients (%)
CR 5 (11)
PR 18 (40)
NC 9 (20)
PD 8 (18)
Early termination of treatment 5 (11)
Survival
Median overall survival 14 months [2–36+ months]
Median progression-free survival 9 months [1–36+ months]within 5 days. Only one patient had to be admitted to the hospital
for WHO grade III fever and infection. This patient quickly
responded to antibiotics without further complications, although
the focus of the infection could not be detected. There was no
WHO grade III°/IV° thrombocytopenia. The major WHO grade
III/IV non-haematological toxicities were alopecia (71%),
nausea/vomiting (11%) and mucositis (4%). No severe hand-foot
syndrome was observed. In five patients treatment had to be
stopped within the first cycle of therapy due to acute toxicities as
stated above. Dose reductions (7 patients; 16%) and/or treatment
delays (1 patient; 2%) were necessary in 8 patients (18%), in 
7 patients due to neutropenia WHO grade III/IV and in 1 patient
due to WHO grade III diarrhea. No dose reduction was performed
due to neurotoxicity.
DISCUSSION
Second generation protocols for the treatment of advanced gastric
cancer are mainly based on 5-FU, high-dose MTX, cisplatin and
antracyclines. In phase II trials, response rates up to 60% have
been reported for regimens such as FAMTX, ELF, EAP,
Cisplatin/5-FU or ECF (Klein et al, 1986; Preusser et al, 1989;
Wilke et al, 1990; Findley and Cunningham, 1993; Wils, 1996).
However, in randomised phase III trials, this high level of activity
has only been confirmed for the ECF-regimen (Webb et al, 1997;
Waters et al, 1999), whereas for the FAMTX, ELF or cisplatin/5-
FU-regimen response rates of 20–25% have been reported (Kelsen
et al, 1992; Wilke et al, 1995). In addition, particularly the
FAMTX and EAP regimens were associated with severe toxicity.
Thus, to date, ECF appears to be the most active regimen, but a
definitive standard regimen for the palliative treatment of
metastatic gastric cancer has not yet been defined.
Several new agents have been tested in gastric cancer in the past
years including topoisomerase I inhibitors such as CPT-11 or
taxanes such as paclitaxel. In vitro and in vivo data appear to support
the use of paclitaxel in gastric cancer (Chang et al, 1996; Ajani et al,
1998; Cascinu et al, 1998). An additive cytotoxic effect has been
reported in vitro for the sequence of paclitaxel followed by 5-FU
whereas the exposure to 5-FU followed by paclitaxel showed subad-
ditive effects (Kano et al, 1996). Based on these rationale we had
previously performed a phase II trial examining the efficacy and
toxicity of the combination of paclitaxel, 5-FU and folinic acid in 22
patients with chemonaive gastric cancer (Bokemeyer et al, 1997a).
A response rate of 32% and a median overall survival of 11 months
were achieved. Toxicity was low with neutropenia WHO grade
III/IV occurring in 14% of patients. In the study presented here as
well as in our previous study, 5-FU was administered as a protracted,
weekly 24 h infusion combined with folinic acid, since this mode of
application appears to be less toxic and potentially more active as
compared to the bolus administration. This regimen was initially
investigated in patients with colon cancer and showed a good
activity with low toxicity (Ardalan et al, 1991). In gastric cancer,
one study had reported the use of protracted 24 h continuous infu-
sion of high-dose 5-FU achieving a remission rate of 24% and a
stable disease rate of 59% in patients previously treated with bolus
5-FU therapy (Vanhoefer et al, 1994). Thus, the weekly administra-
tion of 24 h continuous infusion of high-dose 5-FU (2000 mg/m2)
preceded by folinic acid (500 mg/m2 as 2-h infusion) has formed the
backbone for the development of our treatment regimen. Paclitaxel
was added at a standard-dose of 175 mg/m2 on days 1 and 22.
The present study investigates the efficacy and toxicity of the
same regimen of paclitaxel and weekly 24-hour continuous infu-
sion 5-FU plus folinic acid, but with the addition of cisplatin.
Cisplatin has been shown to be active in gastric cancer as a single
agent as well as in combination with 5-FU (Rougier et al, 1994;
Schipper and Wagener, 1996; Wilke et al, 1996b). Furthermore, a
synergistic effect has been described not only for the combina-
tion of 5-FU and cisplatin (Schabel et al, 1979; Scanlon et al,
1986) but also for the combination of paclitaxel and cisplatin in
human gastric cancer cell lines (Harstrick et al, 1994). In order to
avoid intensive toxicity in palliatively treated patients, cisplatin
was given in a dose of 50 mg/m2 on days 8 and 29. An objective
response rate of 51% – or 58% if only those patients receiving at
least one complete cycle of therapy are taken into account –
including 11% (13%) complete remissions in chemonaive gastric
cancer patients demonstrates the high activity of this regimen. A
similar favourable response rate of 51% with a median survival
time of 6 months was recently achieved by Kim et al (1999)
administering paclitaxel at a dose of 175 mg/m2 on day 1, 5-FU
at a dose of 750 mg/m2 on days 1–5 as continuous infusion and
cisplatin at a dose of 20 mg/m2 as a 30 minute infusion on days
1–5. In patients with adenocarcinoma of the oesophagus, Ilson et
al (1998) reported a response rate of 46% with a similar
schedule. The median overall and progression-free survival of 14
and 9 months duration, respectively, in the current study are
encouraging. The addition of cisplatin to our previous regimen
consisting of paclitaxel and 5-FU/folinic acid appears to improve
the overall response rate, in particular the number of complete
responses and the median survival time (Bokemeyer et al,
1997b).
The toxicity of the present combination of paclitaxel, 24 h
continuous infusion of high-dose 5-FU/folinic acid and cisplatin
was acceptable and the treatment could be safely administered on
an outpatient basis. Only one patient had to be hospitalized due to
fever and infection. Dose reductions or treatment delays were
performed in 18% of patients, mainly due to neutropenia. More
than 60% of the patients who participated in the quality of life
evaluation reported an improvement or stabilization of their symp-
toms and general condition. This clinical benefit not only reflects
the favourable toxicity profile but also demonstrates the palliative
effect of this regimen.
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Table 3 Toxicity (worst toxicity per patients during study (n = 45))
Toxicity WHO grade I/II WHO grade III/IV
No. patients (%) No. patients (%)
Neutropenia 24 (53) 7 (15)
Thrombocytopenia 3 (7) 0
Fever/infection 8 (18) 1 (2)
Alopecia 13 (29) 27 (71)
Nausea/vomiting 20 (44) 5 (11)
Mucositis 15 (33) 2 (4)
Allergy 0 1 (2)b
Neurotoxicity 15 (33) 1 (2)a
Diarrhoea 11 (24) 1 (2)
Hand-food syndrome 5 (11) 0
Constipation 9 (20) 0
Myalgia 9 (20) 0
Nephrotoxicity 10 (22) 0
Other 0 1 (2) a(cardiotox)
aProbably 5-FU related.
bFlush, generalized urticaria and exanthema.However, results of phase II trials have to be carefully inter-
preted since patient selection may cause a bias and subsequently
misleading results. Thus, in order to confirm the high activity of
the current regimen and in order to define the role of paclitaxel,
randomized phase III trials are needed. The EORTC study 40953
has compared ELF to FAMTX and to 5-FU/folinic acid as well as
to 5-FU/folinic acid plus cisplatin. Results of this study may yield
a control arm for future randomized trials. Due to its high response
rate and its moderate toxicity allowing outpatient treatment, the
combination of high-dose 5-FU/folinic acid, cisplatin plus pacli-
taxel may be an attractive option to be tested in neoadjuvant or
adjuvant trials in patients with locally advanced disease.
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